Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2009

View Archived Issues

Route of administration affects immunoglobulin use in immunodeficiency patients

Prostate cancer patients' survival predicted by radiologic progression improves with new vaccine

Novel b-Raf inhibitors claimed by Takeda

Statin-induced atherosclerotic plaque regression is more effective in women than men

Shanghai Hengrui discloses dipeptidyl peptidase IV inhibitors for diabetes

New heat shock protein 90 inhibitors investigated for effects in Alzheimer's disease

Synairgen reports preliminary findings from phase I trial of IFN-beta biomarker neopterin

First patient treated in Osiris' phase II stem cell trial for myocardial infarction

Intercell's Ixiaro approved in Europe to prevent Japanese encephalitis

Micromet receives milestone payment from Nycomed for MT-203

Gilead's phase III darusentan study for hypertension meets primary endpoints

Phase III results reported for Labopharm's twice-daily tramadol/acetaminophen combination

CV Technologies changes name to Afexa Life Sciences as part of rebranding plan

StemCells acquires Stem Cell Sciences

Enrollment completed in Depomed's phase III trial of Serada in menopausal hot flashes

Pfizer discontinues one of its phase III trials of Sutent in advanced breast cancer

InSite Vision and Nitten sign international licensing and distribution agreement for AzaSite

Novel Raf kinase inhibitors presented by GlaxoSmithKline

Orchid Research Laboratories presents novel monoamine oxidase inhibitors

Novel bile acid responsive receptor ligands discovered by Kalypsus

Novel mu-opioid receptor ligands developed by OSI Prosidion for the treatment of obesity

Low-molecular-weight allosteric inhibitor of luteinizing hormone receptor identified

Priligy reaches first market

Alnylam initiates phase I ALN-VSP trial in patients with liver cancer

FDA grants priority review for Genmab's Arzerra

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...